111 related articles for article (PubMed ID: 20824700)
1. Farnesyl transferase inhibitor treatment of breast cancer cells leads to altered RhoA and RhoC GTPase activity and induces a dormant phenotype.
Chatterjee M; van Golen KL
Int J Cancer; 2011 Jul; 129(1):61-9. PubMed ID: 20824700
[TBL] [Abstract][Full Text] [Related]
2. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor.
van Golen KL; Bao L; DiVito MM; Wu Z; Prendergast GC; Merajver SD
Mol Cancer Ther; 2002 Jun; 1(8):575-83. PubMed ID: 12479217
[TBL] [Abstract][Full Text] [Related]
3. Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo.
Pillé JY; Denoyelle C; Varet J; Bertrand JR; Soria J; Opolon P; Lu H; Pritchard LL; Vannier JP; Malvy C; Soria C; Li H
Mol Ther; 2005 Feb; 11(2):267-74. PubMed ID: 15668138
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho.
Kusama T; Mukai M; Tatsuta M; Nakamura H; Inoue M
Int J Oncol; 2006 Jul; 29(1):217-23. PubMed ID: 16773203
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
6. Rho isoform-specific interaction with IQGAP1 promotes breast cancer cell proliferation and migration.
Casteel DE; Turner S; Schwappacher R; Rangaswami H; Su-Yuo J; Zhuang S; Boss GR; Pilz RB
J Biol Chem; 2012 Nov; 287(45):38367-78. PubMed ID: 22992742
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor stimulates human trophoblast cell migration through Rho A and Rho C activation.
Han J; Li L; Hu J; Yu L; Zheng Y; Guo J; Zheng X; Yi P; Zhou Y
Endocrinology; 2010 Apr; 151(4):1732-42. PubMed ID: 20150581
[TBL] [Abstract][Full Text] [Related]
8. Specific induction of migration and invasion of pancreatic carcinoma cells by RhoC, which differs from RhoA in its localisation and activity.
Dietrich KA; Schwarz R; Liska M; Grass S; Menke A; Meister M; Kierschke G; Längle C; Genze F; Giehl K
Biol Chem; 2009 Oct; 390(10):1063-77. PubMed ID: 19642867
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancers.
Wu M; Wu ZF; Rosenthal DT; Rhee EM; Merajver SD
Cancer; 2010 Jun; 116(11 Suppl):2768-82. PubMed ID: 20503409
[TBL] [Abstract][Full Text] [Related]
10. RhoA and RhoC proteins promote both cell proliferation and cell invasion of human oesophageal squamous cell carcinoma cell lines in vitro and in vivo.
Faried A; Faried LS; Kimura H; Nakajima M; Sohda M; Miyazaki T; Kato H; Usman N; Kuwano H
Eur J Cancer; 2006 Jul; 42(10):1455-65. PubMed ID: 16750623
[TBL] [Abstract][Full Text] [Related]
11. Caveolin-1 mediates inflammatory breast cancer cell invasion via the Akt1 pathway and RhoC GTPase.
Joglekar M; Elbezanti WO; Weitzman MD; Lehman HL; van Golen KL
J Cell Biochem; 2015 Jun; 116(6):923-33. PubMed ID: 25559359
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer stem cells survive periods of farnesyl-transferase inhibitor-induced dormancy by undergoing autophagy.
Chaterjee M; van Golen KL
Bone Marrow Res; 2011; 2011():362938. PubMed ID: 22046561
[TBL] [Abstract][Full Text] [Related]
13. Regulation of inflammatory breast cancer cell invasion through Akt1/PKBα phosphorylation of RhoC GTPase.
Lehman HL; Van Laere SJ; van Golen CM; Vermeulen PB; Dirix LY; van Golen KL
Mol Cancer Res; 2012 Oct; 10(10):1306-18. PubMed ID: 22896661
[TBL] [Abstract][Full Text] [Related]
14. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype.
van Golen KL; Wu ZF; Qiao XT; Bao LW; Merajver SD
Cancer Res; 2000 Oct; 60(20):5832-8. PubMed ID: 11059780
[TBL] [Abstract][Full Text] [Related]
15. Clinical and prognostic significance of RhoA and RhoC gene expression in esophageal squamous cell carcinoma.
Faried A; Faried LS; Usman N; Kato H; Kuwano H
Ann Surg Oncol; 2007 Dec; 14(12):3593-601. PubMed ID: 17896152
[TBL] [Abstract][Full Text] [Related]
16. [Farnesyl transferase inhibitors--a novel agent for breast cancer].
Zhang M; Jiang D
Ai Zheng; 2006 Apr; 25(4):516-20. PubMed ID: 16613692
[TBL] [Abstract][Full Text] [Related]
17. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
Omer CA; Chen Z; Diehl RE; Conner MW; Chen HY; Trumbauer ME; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams MT; Davide JP; Ellis MS; Gibbs JB; Greenberg I; Koblan KS; Kral AM; Liu D; Lobell RB; Miller PJ; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Senderak ET; Oliff A; Kohl NE
Cancer Res; 2000 May; 60(10):2680-8. PubMed ID: 10825141
[TBL] [Abstract][Full Text] [Related]
18. RhoGDIα-dependent balance between RhoA and RhoC is a key regulator of cancer cell tumorigenesis.
Giang Ho TT; Stultiens A; Dubail J; Lapière CM; Nusgens BV; Colige AC; Deroanne CF
Mol Biol Cell; 2011 Sep; 22(17):3263-75. PubMed ID: 21757538
[TBL] [Abstract][Full Text] [Related]
19. Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma.
Simpson KJ; Dugan AS; Mercurio AM
Cancer Res; 2004 Dec; 64(23):8694-701. PubMed ID: 15574779
[TBL] [Abstract][Full Text] [Related]
20. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
